Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AEON Stock Forecast 2026-2027
$0.50
Current Price
$13.22M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AEON Price Targets
+1,571.0%
To High Target of $8.40
+1,232.8%
To Median Target of $6.70
+894.6%
To Low Target of $5.00
AEON Price Momentum
-29.6%
1 Week Change
-29.6%
1 Month Change
-41.9%
1 Year Change
-54.5%
Year-to-Date Change
-65.3%
From 52W High of $1.45
+0.5%
From 52W Low of $0.50
📊 TOP ANALYST CALLS
Did AEON Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AEON Biopharma is one of their latest high-conviction picks.
Latest AEON Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, AEON has a bullish consensus with a median price target of $6.70 (ranging from $5.00 to $8.40). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.50, the median forecast implies a 1,232.8% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AEON Analyst Ratings
2
Buy
0
Hold
0
Sell
AEON Price Target Range
Low
$5.00
Average
$6.70
High
$8.40
Current: $0.50
Latest AEON Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AEON.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 8, 2025 | Aegis Capital | Buy | Reiterates | $N/A | |
| Oct 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 14, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 30, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 15, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 17, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 18, 2023 | HC Wainwright & Co. | Buy | Initiates | $N/A |
Aeon Biopharma Inc. (AEON) Competitors
The following stocks are similar to AEON Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AEON
AEON Biopharma
mkt cap
18.81M
Aeon Biopharma Inc. (AEON) Financial Data
Aeon Biopharma Inc. has a market capitalization of $13.22M with a P/E ratio of 0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +71.3%.
Valuation Metrics
Market Cap
$13.22M
Enterprise Value
$15.59M
P/E Ratio
0.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+47.1%
Current Ratio
1.0x
Debt/Equity
-0.2x
ROE
+71.3%
ROA
-101.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aeon Biopharma Inc. (AEON) Business Model
About Aeon Biopharma Inc.
What They Do
Develops therapeutic treatments for medical conditions.
Business Model
Aeon Biopharma Inc. operates within the biopharmaceutical sector, focusing on the research and development of innovative therapies. The company generates revenue through the commercialization of its therapeutic products, which aim to improve patient outcomes in neurology and chronic disorders, thereby addressing unmet medical needs.
Additional Information
The company emphasizes cutting-edge research methodologies and strategic partnerships to advance its therapeutic offerings. By targeting conditions that are often deemed untreatable, Aeon Biopharma positions itself as a key player in the medical innovation landscape, appealing to healthcare providers and patients alike.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Mr. Robert Bancroft
Country
United States
IPO Year
2023
Website
www.aeonbiopharma.comAeon Biopharma Inc. (AEON) Latest News & Analysis
Latest News
Quick Summary
AEON Biopharma presented new data on ABP-450, a biosimilar to BOTOX®, at the AHS meeting, supporting its market entry for therapeutic use.
Why It Matters
The presentation of data supporting ABP-450's biosimilarity to BOTOX® could enhance AEON's market position, potentially increasing investor confidence and driving stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
1 month ago
Quick Summary
AEON Biopharma reported positive FDA meeting results for ABP-450, improved its balance sheet by reducing debt over 90%, and appointed John Bencich as CFO in its Q1 2026 update.
Why It Matters
Positive FDA meeting boosts ABP-450's market prospects, while significant debt reduction and a new CFO enhance financial stability, signaling strong growth potential for AEON Biopharma.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AEON Biopharma Sets Annual Shareholder Meeting
2 months ago
Quick Summary
AEON Biopharma, Inc. will hold its Annual Shareholder Meeting on June 17, 2026, at 10:00 am PT at its Irvine, CA offices. The company is advancing ABP-450 as a biosimilar to BOTOX®.
Why It Matters
The announcement of the Annual Shareholder Meeting provides a timeline for investors to assess company progress and potential developments regarding AEON’s biosimilar product, ABP-450.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
3 months ago
Quick Summary
AEON Biopharma, Inc. (NYSE American: AEON) received a notice from NYSE American on March 31, 2026, indicating non-compliance with listing standards following its year-end financial results.
Why It Matters
AEON Biopharma's non-compliance with NYSE listing standards raises concerns over financial stability, potentially impacting stock value and investor confidence in its market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
3 months ago
Quick Summary
AEON Biopharma appointed John Bencich as CFO and the Compensation Committee approved inducement awards related to his appointment. The company is advancing its biosimilar ABP-450 toward U.S. market entry.
Why It Matters
The appointment of a new CFO and inducement awards may signal a strategic shift or renewed focus, potentially impacting AEON's financial health and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AEON Biopharma announced its full-year 2025 financial results, highlighting favorable analytical results and positive FDA feedback for its ABP-450 biosimilar program.
Why It Matters
Positive financial results and FDA feedback for AEON Biopharma's ABP-450 biosimilar indicate potential market confidence and future revenue growth, influencing investment decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About AEON Stock
What is Aeon Biopharma Inc.'s (AEON) stock forecast for 2027?
Based on our analysis of 1 Wall Street analysts, Aeon Biopharma Inc. (AEON) has a median price target of $6.70. The highest price target is $8.40 and the lowest is $5.00.
Is AEON stock a good investment in 2027?
According to current analyst ratings, AEON has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AEON stock?
Wall Street analysts predict AEON stock could reach $6.70 in the next 12 months. This represents a 1,232.8% increase from the current price of $0.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aeon Biopharma Inc.'s business model?
Aeon Biopharma Inc. operates within the biopharmaceutical sector, focusing on the research and development of innovative therapies. The company generates revenue through the commercialization of its therapeutic products, which aim to improve patient outcomes in neurology and chronic disorders, thereby addressing unmet medical needs.
What is the highest forecasted price for AEON Aeon Biopharma Inc.?
The highest price target for AEON is $8.40 from at , which represents a 1,571.0% increase from the current price of $0.50.
What is the lowest forecasted price for AEON Aeon Biopharma Inc.?
The lowest price target for AEON is $5.00 from at , which represents a 894.6% increase from the current price of $0.50.
What is the overall AEON consensus from analysts for Aeon Biopharma Inc.?
The overall analyst consensus for AEON is bullish. Out of 1 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.70.
How accurate are AEON stock price projections?
Stock price projections, including those for Aeon Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 10, 2026 5:03 AM UTC